| Year |
Citation |
Score |
| 2021 |
Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, ... Hurwitz H, et al. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology. 13: 17588359211020547. PMID 34262614 DOI: 10.1177/17588359211020547 |
0.321 |
|
| 2021 |
Morse M, Halperin DM, Uronis HE, Hsu DS, Hurwitz H, Bolch E, Warren D, Haley S, John L, Moyer A, Rushing CN, Niedzwiecki D. Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET). Journal of Clinical Oncology. 39: 369-369. DOI: 10.1200/JCO.2021.39.3_SUPPL.369 |
0.327 |
|
| 2021 |
Uronis HE, Rushing C, Blobe GC, Hsu SD, Mettu NB, Wells JL, Niedzwiecki D, Hartman L, Moyer A, Hurwitz HI, Strickler JH. KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma. Journal of Clinical Oncology. 39: 228-228. DOI: 10.1200/JCO.2021.39.3_SUPPL.228 |
0.322 |
|
| 2020 |
Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001225. PMID 32816630 DOI: 10.1200/JCO.20.01225 |
0.319 |
|
| 2020 |
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews. 86: 102017. PMID 32335505 DOI: 10.1016/j.ctrv.2020.102017 |
0.369 |
|
| 2020 |
Max Ma X, Bendell JC, Hurwitz HI, Ju C, Lee JJ, Lovejoy A, Mancao C, Nicholas A, Price R, Sommer N, Tikoo N, Yao L, Yaung SJ, Palma JF. Disease Monitoring Using Post-Induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32220893 DOI: 10.1158/1078-0432.CCR-19-1209 |
0.309 |
|
| 2020 |
Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O'Malley DM, Gray H, Bakkum-Gamez JN, et al. Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31919136 DOI: 10.1158/1078-0432.Ccr-19-0226 |
0.342 |
|
| 2019 |
Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, Hsu SD, Zafar SY, Morse MA, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Arrowood C, Bolch E, ... ... Hurwitz HI, et al. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. Bmc Cancer. 19: 1032. PMID 31675952 DOI: 10.1186/s12885-019-6234-8 |
0.389 |
|
| 2019 |
Bendell JC, Sauri T, Gracián AC, Alvarez R, López-López C, García-Alfonso P, Hussein M, Miron ML, Cervantes A, Montagut C, Vivas CS, Bessudo A, Plezia P, Moons V, Andel J, ... ... Hurwitz H, et al. The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). The Oncologist. PMID 31570519 DOI: 10.1634/theoncologist.2019-0291 |
0.402 |
|
| 2019 |
Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar SY, Morse M, Dropkin E, Howard L, O'Neill M, Rushing CN, Niedzwiecki D, Watson H, Bolch E, Arrowood C, Liu Y, ... ... Hurwitz HI, et al. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). Cancer Chemotherapy and Pharmacology. PMID 31444620 DOI: 10.1007/S00280-019-03916-0 |
0.392 |
|
| 2019 |
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. The Lancet. Oncology. PMID 30857956 DOI: 10.1016/S1470-2045(18)30904-5 |
0.313 |
|
| 2018 |
Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). The Oncologist. PMID 30552157 DOI: 10.1634/theoncologist.2018-0344 |
0.388 |
|
| 2018 |
Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Talbot J, Srock S, Lenz HJ. Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer. PMID 30487637 DOI: 10.1038/s41416-018-0304-6 |
0.33 |
|
| 2018 |
Chen DS, Hurwitz H. Combinations of Bevacizumab With Cancer Immunotherapy. Cancer Journal (Sudbury, Mass.). 24: 193-204. PMID 30119083 DOI: 10.1097/Ppo.0000000000000327 |
0.425 |
|
| 2018 |
Liu Y, Starr MD, Brady JC, Rushing C, Pang H, Adams B, Alvarez D, Theuer CP, Hurwitz HI, Nixon AB. Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody TRC105. Molecular Cancer Therapeutics. PMID 29997150 DOI: 10.1158/1535-7163.MCT-17-0916 |
0.302 |
|
| 2018 |
Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: 1108-1119. PMID 29659677 DOI: 10.1093/annonc/mdy100 |
0.308 |
|
| 2018 |
Vlahovic G, Meadows KL, Hatch AJ, Jia J, Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, Zafar SY, Howard LA, O'Neill M, Meadows JJ, Haley ST, ... ... Hurwitz HI, et al. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. The Oncologist. PMID 29572245 DOI: 10.1634/Theoncologist.2016-0377 |
0.326 |
|
| 2018 |
Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investigational New Drugs. PMID 29508247 DOI: 10.1007/s10637-018-0580-2 |
0.34 |
|
| 2018 |
Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017753780. PMID 29320312 DOI: 10.1200/Jco.2017.75.3780 |
0.321 |
|
| 2018 |
Mettu NB, Niedzwiecki D, Boland PM, Fakih M, Arrowood C, Bolch E, Hurwitz H, Grothey A. BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer. Journal of Clinical Oncology. 36: TPS873-TPS873. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps873 |
0.412 |
|
| 2017 |
Chan E, Chiorean EG, O'Dwyer PJ, Gabrail NY, Alcindor T, Potvin D, Chao R, Hurwitz H. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 29238851 DOI: 10.1007/s00280-017-3494-3 |
0.372 |
|
| 2017 |
Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall J, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA. A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Ontuxizumab (MORAb-004) in Patients with Chemorefractory Metastatic Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29084918 DOI: 10.1158/1078-0432.CCR-17-1558 |
0.395 |
|
| 2017 |
García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, ... ... Hurwitz H, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. The Oncologist. 22: 1281. PMID 29018169 DOI: 10.1634/theoncologist.2016-0133erratum |
0.349 |
|
| 2017 |
García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, ... ... Hurwitz H, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. The Oncologist. PMID 28275117 DOI: 10.1634/Theoncologist.2016-0133 |
0.442 |
|
| 2017 |
Hurwitz H, Raghav KPS, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Vanderwalde AM, Spigel DR, Bose R, Fakih M, Swanton C, Guo S, Bernaards C, Beattie MS, Sommer N, et al. Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Journal of Clinical Oncology. 35: 676-676. DOI: 10.1200/Jco.2017.35.4_Suppl.676 |
0.36 |
|
| 2017 |
Hurwitz H, Tan BR, Reeves JA, Xiong HQ, Somer BG, Lenz H, Hochster HS, Scappaticci F, Palma JF, Mancao C, Lee JJ, Nicholas A, Sommer N, Bendell JC. Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 35: 657-657. DOI: 10.1200/JCO.2017.35.4_SUPPL.657 |
0.318 |
|
| 2017 |
Javle MM, Hainsworth JD, Swanton C, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Spigel DR, Bose R, Guo S, Bernaards C, Beattie MS, Scappaticci FA, Hurwitz H. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. Journal of Clinical Oncology. 35: 402-402. DOI: 10.1200/Jco.2017.35.4_Suppl.402 |
0.364 |
|
| 2017 |
Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Sweeney C, Yoo B, Beattie MS, Patel R, Schulze K, Lam ET. Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. Journal of Clinical Oncology. 35: 6086-6086. DOI: 10.1200/Jco.2017.35.15_Suppl.6086 |
0.37 |
|
| 2017 |
Segal N, Saro J, Melero I, Ros W, Argiles G, Marabelle A, Rodriguez Ruiz M, Albanell J, Calvo E, Moreno V, Cleary J, Eder J, Karanikas V, Bouseida S, Sandoval F, ... ... Hurwitz H, et al. Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC) Annals of Oncology. 28: v134. DOI: 10.1093/ANNONC/MDX367.036 |
0.307 |
|
| 2016 |
Strickler JH, Rangwala FA, Rushing C, Niedzwiecki D, Altomare I, Uronis HE, Hsu SD, Zafar Y, Morse M, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Webb AR, Dropkin E, ... ... Hurwitz H, et al. X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 34: 687-687. DOI: 10.1200/jco.2016.34.4_suppl.687 |
0.311 |
|
| 2016 |
Nixon AB, Sibley A, Hatch AJ, Liu Y, Jiang C, Mulkey F, Starr MD, Brady JC, Niedzwiecki D, Innocenti F, Venook AP, Hochster HS, Lenz H, O'Neil BH, Owzar K, ... Hurwitz H, et al. Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance). Journal of Clinical Oncology. 34: 3597-3597. DOI: 10.1200/Jco.2016.34.15_Suppl.3597 |
0.389 |
|
| 2016 |
Strickler JH, Rushing CN, Uronis HE, Morse M, Blobe GC, Zafar Y, Hsu SD, Arrowood C, Haley S, Dropkin E, Niedzwiecki D, Hurwitz H. Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 34: 3548-3548. DOI: 10.1200/Jco.2016.34.15_Suppl.3548 |
0.315 |
|
| 2016 |
Innocenti F, Jiang C, Sibley A, Etheridge A, Furukawa Y, Kubo M, Kindler HL, Venook AP, Hurwitz HI, Nixon AB, Owzar K. Abstract 3388: Genetic prediction of VEGF-A plasma levels in cancer patients Cancer Research. 76: 3388-3388. DOI: 10.1158/1538-7445.Am2016-3388 |
0.304 |
|
| 2016 |
Wallin J, Pishvaian MJ, Hernandez G, Yadav M, Jhunjhunwala S, Delamarre L, He X, Powderly J, Lieu C, Eckhardt SG, Hurwitz H, Hochster HS, Murphy J, Leveque V, Cha E, et al. Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma Cancer Research. 76: 2651-2651. DOI: 10.1158/1538-7445.Am2016-2651 |
0.31 |
|
| 2015 |
Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, et al. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26351344 DOI: 10.1200/JCO.2015.61.4578 |
0.358 |
|
| 2015 |
Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1230-7. PMID 25787923 DOI: 10.1093/annonc/mdv144 |
0.308 |
|
| 2015 |
Tebbutt N, Kotasek D, Burris HA, Schwartzberg LS, Hurwitz H, Stephenson J, Warner DJ, Chen L, Hsu CP, Goldstein D. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 75: 993-1004. PMID 25772756 DOI: 10.1007/s00280-015-2694-y |
0.349 |
|
| 2015 |
Uronis HE, Jia J, Bendell JC, Howard L, Ready NA, Lee PH, Starr MD, Dellinger A, Pang H, Nixon AB, Hurwitz HI. A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 75: 343-52. PMID 25527204 DOI: 10.1007/S00280-014-2647-X |
0.323 |
|
| 2015 |
Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 22-8. PMID 25385741 DOI: 10.1200/JCO.2014.56.5887 |
0.306 |
|
| 2015 |
Hurwitz H, Garrett WM, Clark J, Brill KJ, Dawkins FW, Hidalgo M, Van Cutsem E. JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy. Journal of Clinical Oncology. 33: TPS4147-TPS4147. DOI: 10.1200/JCO.2015.33.15_SUPPL.TPS4147 |
0.339 |
|
| 2015 |
Burris HA, Hurwitz H, Perez EA, Spigel D, Swanton C, Hainsworth JD, Leon L, Beattie M, Brammer M, Sweeney C. MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps11111 |
0.329 |
|
| 2015 |
Hurwitz H, Zafar Y, Kozloff M, Hubbard J, Van Cutsem E, Bennouna J, Arnold D, Bekaii-Saab T, Srock S, Revil C, Fish S, Barue V, Grothey A. 2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC) European Journal of Cancer. 51: S379-S380. DOI: 10.1016/S0959-8049(16)31062-0 |
0.313 |
|
| 2014 |
Lieu C, Bendell J, Powderly JD, Pishvaian MJ, Hochster H, Eckhardt SG, Funke R, Rossi C, Waterkamp D, Hurwitz H. 1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv361. PMID 28171108 DOI: 10.1093/annonc/mdu342.2 |
0.327 |
|
| 2014 |
Hurwitz H, Tan B, Reeves J, Xiong H, Lenz H, Hochster H, Laeufle R, Sommer N, Young J, Byrtek M, Bendell J. 521PINTERIM SAFETY RESULTS FROM STEAM: A RANDOMIZED PHASE 2 TRIAL OF SEQUENTIAL AND CONCURRENT FOLFOXIRI-BEVACIZUMAB (BEV) VS FOLFOX-BEV FOR THE FIRST-LINE (1L) TREATMENT (TX) OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv177. PMID 28170818 DOI: 10.1093/annonc/mdu333.24 |
0.361 |
|
| 2014 |
Secord AA, Nixon AB, Hurwitz HI. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. Gynecologic Oncology. 135: 349-58. PMID 25178997 DOI: 10.1016/j.ygyno.2014.08.033 |
0.319 |
|
| 2014 |
Pili R, Carducci M, Brown P, Hurwitz H. An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Investigational New Drugs. 32: 1258-68. PMID 25152243 DOI: 10.1007/S10637-014-0147-9 |
0.338 |
|
| 2014 |
Clarke JM, Hurwitz HI, Rangwala F. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. Cancer Treatment Reviews. 40: 1065-72. PMID 25047778 DOI: 10.1016/j.ctrv.2014.07.001 |
0.303 |
|
| 2014 |
Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, Graham A, Busman T, Mabry M, Holen K, Shapiro GI, Uronis H. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Investigational New Drugs. 32: 937-45. PMID 24916770 DOI: 10.1007/s10637-014-0110-9 |
0.309 |
|
| 2014 |
Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, ... ... Hurwitz HI, et al. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Investigational New Drugs. 32: 700-9. PMID 24711126 DOI: 10.1007/s10637-014-0089-2 |
0.313 |
|
| 2014 |
Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clinical Oncology (Royal College of Radiologists (Great Britain)). 26: 323-32. PMID 24686090 DOI: 10.1016/j.clon.2014.03.001 |
0.318 |
|
| 2014 |
Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Current Oncology Reports. 16: 363. PMID 24293074 DOI: 10.1007/s11912-013-0363-z |
0.332 |
|
| 2014 |
Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, ... ... Hurwitz HI, et al. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investigational New Drugs. 32: 330-9. PMID 24173967 DOI: 10.1200/Jco.2011.29.15_Suppl.3586 |
0.346 |
|
| 2014 |
Bendell JC, Tan BR, Reeves JA, Xiong HQ, Laeufle R, Byrtek M, Sommer N, Hurwitz H. STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 32: TPS3652-TPS3652. DOI: 10.1200/JCO.2014.32.15_SUPPL.TPS3652 |
0.348 |
|
| 2014 |
Hurwitz H, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade S, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, et al. A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). Journal of Clinical Oncology. 32: 4000-4000. DOI: 10.1200/JCO.2014.32.15_SUPPL.4000 |
0.353 |
|
| 2014 |
Grothey A, Arnold D, Van Cutsem E, Bekaii-Saab T, Kozloff M, Bennouna J, Revil C, Donica M, Sommer N, Leutgeb B, Ekstrand-Olsen M, Hermann F, Hurwitz H. Overall Survival According to Patient Subgroups: Results from a Pooled Analysis of 5 Observational or Phase Iv Studies of Bevacizumab in Metastatic Colorectal Cancer Annals of Oncology. 25: iv176. DOI: 10.1093/annonc/mdu333.23 |
0.359 |
|
| 2014 |
Hurwitz H, Uppal N, Wagner S, Bendell J, Thaddeus B, Wade S, Nemunaitis J, Stella P, Pipas J, Wainberg Z, Manges R, Garrett W, Hunter D, Clark J, Leopold L, et al. Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial Annals of Oncology. 25: ii115. DOI: 10.1093/ANNONC/MDU193.26 |
0.352 |
|
| 2013 |
Mettu NB, Hurwitz H, Hsu DS. Use of molecular biomarkers to inform adjuvant therapy for colon cancer. Oncology (Williston Park, N.Y.). 27: 746-54. PMID 24133820 |
0.314 |
|
| 2013 |
Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6957-66. PMID 24097873 DOI: 10.1158/1078-0432.CCR-13-0926 |
0.346 |
|
| 2013 |
Uronis HE, Cushman SM, Bendell JC, Blobe GC, Morse MA, Nixon AB, Dellinger A, Starr MD, Li H, Meadows K, Gockerman J, Pang H, Hurwitz HI. A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Medicine. 2: 316-24. PMID 23930208 DOI: 10.1002/Cam4.65 |
0.382 |
|
| 2013 |
Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. The Oncologist. 18: 1004-12. PMID 23881988 DOI: 10.1634/theoncologist.2013-0107 |
0.337 |
|
| 2013 |
Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opinion On Biological Therapy. 13: 1187-96. PMID 23803182 DOI: 10.1517/14712598.2013.810717 |
0.359 |
|
| 2013 |
Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, ... Hurwitz HI, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. The Oncologist. 18: 271-2. PMID 23485624 DOI: 10.1634/Theoncologist.2012-0404 |
0.306 |
|
| 2013 |
Clarke JM, Hurwitz HI. Ziv-aflibercept: binding to more than VEGF-A--does more matter? Nature Reviews. Clinical Oncology. 10: 10-1. PMID 23149898 DOI: 10.1038/nrclinonc.2012.197 |
0.329 |
|
| 2013 |
de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Investigational New Drugs. 31: 751-9. PMID 23054212 DOI: 10.1007/s10637-012-9885-8 |
0.313 |
|
| 2013 |
Strickler JH, McCall S, Nixon AB, Pang H, Rushing C, Arrowood C, Haley S, Meadows K, Hurwitz H. Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors. Journal of Clinical Oncology. 31: 11036-11036. DOI: 10.1200/JCO.2013.31.15_SUPPL.11036 |
0.326 |
|
| 2013 |
Meadows KL, Lee PH, Riedel RF, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Hurwitz HI. Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C61 |
0.353 |
|
| 2012 |
Rangwala FA, Bendell JC, Kozloff M, Arrowood C, Meadows J, Tourt-Uhlig SE, Murphy J, Meadows K, Morse M, Uronis HE, Hsu SD, Zafar Y, Hurwitz H. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 490. PMID 27983003 DOI: 10.1200/jco.2012.30.4_suppl.490 |
0.305 |
|
| 2012 |
Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, Morse MA, Uronis HE, Marcom PK, Zafar SY, Haley ST, Hurwitz HI. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70: 251-8. PMID 22744359 DOI: 10.1007/S00280-012-1911-1 |
0.321 |
|
| 2012 |
Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3170-9. PMID 22661587 DOI: 10.1158/1078-0432.CCR-11-3005 |
0.314 |
|
| 2012 |
Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70: 95-102. PMID 22638798 DOI: 10.1007/S00280-012-1889-8 |
0.316 |
|
| 2012 |
Hurwitz H, Mitchell EP, Cartwright T, Kwok A, Hu S, McKenna E, Patt YZ. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). The Oncologist. 17: 937-46. PMID 22622147 DOI: 10.1634/theoncologist.2012-0071 |
0.335 |
|
| 2012 |
Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. The Oncologist. 17: 513-24. PMID 22477726 DOI: 10.1634/theoncologist.2012-0003 |
0.362 |
|
| 2012 |
Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 577-84. PMID 22142827 DOI: 10.1158/1078-0432.Ccr-11-1387 |
0.313 |
|
| 2012 |
Zafar S, Grothey A, Bekaii-Saab T, Bendell J, Sherrill B, Bennett L, Mun Y, Sersch M, Dalal D, Hurwitz H. Survival Among Metastatic Colorectal Cancer (MCRC) Patients Treated in a Randomized Controlled Trial (RCT) vs an Observational Cohort Study (OCS) Annals of Oncology. 23: ix191. DOI: 10.1016/s0923-7534(20)33170-7 |
0.334 |
|
| 2011 |
Nixon AB, Pang H, Starr M, Hollis D, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz H. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10508. PMID 28022380 DOI: 10.1200/jco.2011.29.15_suppl.10508 |
0.347 |
|
| 2011 |
Strickler JH, Cohn AL, Arrowood C, Haley S, Morse M, Uronis H, Blobe GC, Hsu SD, Zafar Y, Hurwitz H. Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3586. PMID 28020244 DOI: 10.1200/jco.2011.29.15_suppl.3586 |
0.355 |
|
| 2011 |
Starodub A, Cohn AL, Arrowood C, Haley S, Morse M, Uronis HE, Blobe GC, Hsu SD, Zafar Y, Hurwitz H. Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 513. PMID 27985744 DOI: 10.1200/jco.2011.29.4_suppl.513 |
0.356 |
|
| 2011 |
Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, Sutton L, Hurwitz HI. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. The Oncologist. 16: 1131-7. PMID 21795432 DOI: 10.1634/Theoncologist.2011-0078 |
0.43 |
|
| 2011 |
Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirzén F, Lyman GH, Rohr UP. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1757-64. PMID 21422411 DOI: 10.1200/JCO.2010.32.3220 |
0.322 |
|
| 2011 |
Wong NS, Fernando NH, Nixon AB, Cushman S, Aklilu M, Bendell JC, Morse MA, Blobe GC, Ashton J, Pang H, Hurwitz HI. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Research. 31: 255-61. PMID 21273607 |
0.365 |
|
| 2011 |
Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. British Journal of Cancer. 104: 413-8. PMID 21245868 DOI: 10.1038/sj.bjc.6606074 |
0.323 |
|
| 2011 |
Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Mueller B, Sirzén F. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 83-8. PMID 21098326 DOI: 10.1200/JCO.2010.30.2794 |
0.344 |
|
| 2011 |
Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, et al. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemotherapy and Pharmacology. 67: 465-74. PMID 21079958 DOI: 10.1007/S00280-010-1507-6 |
0.338 |
|
| 2010 |
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3617-22. PMID 20606091 DOI: 10.1200/JCO.2010.28.1386 |
0.38 |
|
| 2010 |
Altomare I, Russell KB, Uronis HE, Morse M, Hsu SD, Zafar Y, Bendell JC, Starodub A, Honeycutt W, Hurwitz H. Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 28: 3535-3535. DOI: 10.1200/JCO.2010.28.15_SUPPL.3535 |
0.315 |
|
| 2009 |
Bullock KE, Hurwitz HI, Uronis HE, Morse MA, Blobe GC, Hsu SD, Zafar SY, Nixon AB, Howard LA, Bendell JC. Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4080. PMID 27961646 DOI: 10.1200/Jco.2009.27.15_Suppl.4080 |
0.321 |
|
| 2009 |
Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology. 136: 737-43. PMID 19904559 DOI: 10.1007/s00432-009-0712-3 |
0.348 |
|
| 2009 |
Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. Phase I trial of pazopanib in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4220-7. PMID 19509175 DOI: 10.1158/1078-0432.CCR-08-2740 |
0.35 |
|
| 2009 |
Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials Journal of Clinical Oncology. 27: 199-205. PMID 19064978 DOI: 10.1200/JCO.2008.17.7931 |
0.332 |
|
| 2008 |
Hurwitz H, Nelson B, O'Dwyer PJ, Chiorean EG, Gabrail N, Li Z, Laille E, Drouin M, Rothenberg ML, Chan E. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4625. PMID 27948546 DOI: 10.1200/jco.2008.26.15_suppl.4625 |
0.347 |
|
| 2008 |
Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H. Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? Journal of Empirical Research On Human Research Ethics : Jerhre. 3: 57-68. PMID 19385771 DOI: 10.1525/Jer.2008.3.3.57 |
0.344 |
|
| 2008 |
Kabbinavar F, Irl C, Zurlo A, Hurwitz H. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology. 75: 215-23. PMID 18852492 DOI: 10.1159/000163850 |
0.34 |
|
| 2008 |
Kabbinavar FF, Wallace JF, Holmgren E, Yi J, Cella D, Yost KJ, Hurwitz HI. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer Oncologist. 13: 1021-1029. PMID 18776057 DOI: 10.1634/theoncologist.2008-0003 |
0.315 |
|
| 2008 |
Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 183-9. PMID 18182660 DOI: 10.1200/JCO.2007.13.8099 |
0.342 |
|
| 2008 |
Czito BG, Cohen DP, Kelsey CR, Lockhart AC, Bendell JC, Willett CG, Petros WP, D'Amico TA, Truax R, Hurwitz HI. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma. International Journal of Radiation Oncology, Biology, Physics. 70: 1066-72. PMID 17881149 DOI: 10.1016/j.ijrobp.2007.07.2347 |
0.327 |
|
| 2008 |
Bendell JC, Uronis HE, Morse MA, Blobe G, Aklilu M, Nixon A, Niedzweicki D, Honeycutt W, Howard L, Hurwitz H. Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC) Journal of Clinical Oncology. 26: 4063-4063. DOI: 10.1200/JCO.2008.26.15_SUPPL.4063 |
0.338 |
|
| 2007 |
Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4793-9. PMID 17947727 DOI: 10.1200/JCO.2007.12.8637 |
0.342 |
|
| 2007 |
Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute. 99: 1232-9. PMID 17686822 DOI: 10.1093/jnci/djm086 |
0.307 |
|
| 2007 |
Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. International Journal of Radiation Oncology, Biology, Physics. 68: 472-8. PMID 17498568 DOI: 10.1016/J.Ijrobp.2007.02.001 |
0.39 |
|
| 2007 |
Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nature Clinical Practice. Oncology. 4: 316-21. PMID 17464339 DOI: 10.1038/Ncponc0813 |
0.346 |
|
| 2007 |
Uronis HE, Hurwitz HI. Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer? Nature Clinical Practice. Oncology. 4: 214-5. PMID 17297504 DOI: 10.1038/NCPONC0748 |
0.357 |
|
| 2007 |
Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Seminars in Oncology. 33: S26-34. PMID 17145522 DOI: 10.1053/J.SEMINONCOL.2006.08.001 |
0.351 |
|
| 2007 |
Speca JC, Mears AL, Creel PA, Yenser SE, Bendell JC, Morse MA, Hurwitz HI, Armstrong AJ, George DJ. Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients Journal of Clinical Oncology. 25: 5039-5039. DOI: 10.1200/JCO.2007.25.18_SUPPL.5039 |
0.334 |
|
| 2007 |
Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB Journal of Clinical Oncology. 25: 4508-4508. DOI: 10.1200/Jco.2007.25.18_Suppl.4508 |
0.321 |
|
| 2007 |
Schwartzberg LS, Hurwitz H, Stephenson J, Kotasek D, Goldstein D, Tebbutt N, McGreivy J, Sun Y, Yang L, Burris H. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology. 25: 4081-4081. DOI: 10.1200/Jco.2007.25.18_Suppl.4081 |
0.314 |
|
| 2007 |
Uronis HE, Bendell J, Blobe G, Morse M, Geier D, Nixon A, Howard L, Evans D, Li H, Hurwitz H. A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors Journal of Clinical Oncology. 25: 3541-3541. DOI: 10.1200/JCO.2007.25.18_SUPPL.3541 |
0.381 |
|
| 2007 |
Tabernero J, Cervantes A, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Stuart M, Green TP, Iacona RB, Baselga J. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers Journal of Clinical Oncology. 25: 3520-3520. DOI: 10.1200/JCO.2007.25.18_SUPPL.3520 |
0.305 |
|
| 2006 |
Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4441-7. PMID 16983112 DOI: 10.1200/JCO.2006.07.0201 |
0.342 |
|
| 2006 |
Hurwitz HI, Honeycutt W, Haley S, Favaro J. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. Clinical Colorectal Cancer. 6: 66-9. PMID 16796794 DOI: 10.3816/CCC.2006.N.023 |
0.337 |
|
| 2006 |
Czito BG, Hong TJ, Cohen DP, Petros WP, Tyler DS, Pappas TN, Yu D, Lee CG, Lockhart AC, Morse MA, Fernando N, Hurwitz HI. A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. Cancer Investigation. 24: 9-17. PMID 16466986 DOI: 10.1080/07357900500449454 |
0.308 |
|
| 2006 |
Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 656-62. PMID 16446337 DOI: 10.1200/Jco.2005.04.1749 |
0.365 |
|
| 2006 |
Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 217-27. PMID 16365183 DOI: 10.1200/JCO.2005.01.5388 |
0.307 |
|
| 2006 |
Bendell JC, Fernando N, Morse M, Blobe G, Yu D, Sutton L, Schaffer S, Honeycutt W, Franklin A, Hurwitz H. A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer Journal of Clinical Oncology. 24: 3541-3541. DOI: 10.1200/JCO.2006.24.18_SUPPL.3541 |
0.341 |
|
| 2006 |
Czito B, Willett C, Bendell J, Morse M, Dyler D, Fernando N, Mantyh C, Blobe G, Honeycutt W, Yu D, Clary B, Pappas T, Ludwig K, Hurwitz H. 158 Increased toxicity with gefitinib, capecitabine and radiation in pancreatic and rectal cancer: phase I trial results Radiotherapy and Oncology. 78: S53-S54. DOI: 10.1016/S0167-8140(06)80637-7 |
0.302 |
|
| 2005 |
Chawla A, Holmgren E, Nelson B, Cella D, Yost K, Hurwitz H, Novotny W. Quality of life (QoL) impact of bevacizumab (BV) when combined with irinotecan + 5-FU/leucovorin (IFL) and 5-FU/leucovorin (FL) for metastatic colorectal cancer (mCRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3564. PMID 27944445 DOI: 10.1200/jco.2005.23.16_suppl.3564 |
0.314 |
|
| 2005 |
Mass RD, Sarkar S, Holden SN, Hurwitz H. Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3514. PMID 27944388 DOI: 10.1200/jco.2005.23.16_suppl.3514 |
0.311 |
|
| 2005 |
Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology. 17-24. PMID 16301832 DOI: 10.1159/000088480 |
0.357 |
|
| 2005 |
Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. Journal of Surgical Oncology. 91: 173-80. PMID 16118771 DOI: 10.1002/JSO.20301 |
0.33 |
|
| 2005 |
Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer Journal of Clinical Oncology. 23: 3502-3508. PMID 15908660 DOI: 10.1200/JCO.2005.10.017 |
0.383 |
|
| 2005 |
Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3706-12. PMID 15867200 DOI: 10.1200/JCO.2005.00.232 |
0.404 |
|
| 2005 |
Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Seminars in Oncology. 32: 61-8. PMID 15726507 DOI: 10.1053/j.seminoncol.2004.09.026 |
0.309 |
|
| 2005 |
Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clinical Colorectal Cancer. S62-8. PMID 15479481 DOI: 10.3816/CCC.2004.S.010 |
0.353 |
|
| 2005 |
Fernando N, Yu D, Morse M, Blobe G, Odogwu L, Crews J, Polito A, Honeycutt W, Franklin A, Hurwitz H. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer Journal of Clinical Oncology. 23: 3556-3556. DOI: 10.1200/JCO.2005.23.16_SUPPL.3556 |
0.327 |
|
| 2005 |
Hambleton J, Skillings J, Kabbinavar F, Bergsland E, Holmgren E, Holden SN, Hurwitz H, Scappaticci F. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology. 23: 3554-3554. DOI: 10.1200/JCO.2005.23.16_SUPPL.3554 |
0.33 |
|
| 2004 |
Hambleton J, Novotny WF, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3528. PMID 28016525 DOI: 10.1200/jco.2004.22.14_suppl.3528 |
0.41 |
|
| 2004 |
Hedrick EE, Hurwitz H, Sarkar S, Griffing S, Novotny W, Grothey A. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3517. PMID 28016467 DOI: 10.1200/jco.2004.22.14_suppl.3517 |
0.353 |
|
| 2004 |
Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E, Novotny W. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3617. PMID 28014325 DOI: 10.1200/jco.2004.22.14_suppl.3617 |
0.381 |
|
| 2004 |
Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Novotny W, Scappaticci F. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3702. PMID 28013689 DOI: 10.1200/jco.2004.22.14_suppl.3702 |
0.372 |
|
| 2004 |
Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: Clinical experience with bevacizumab Oncologist. 9: 11-18. PMID 15178811 DOI: 10.1634/theoncologist.9-suppl_1-11 |
0.427 |
|
| 2004 |
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine. 350: 2335-42. PMID 15175435 DOI: 10.1056/NEJMoa032691 |
0.36 |
|
| 2004 |
Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E, Novotny W. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups Journal of Clinical Oncology. 22: 3617-3617. DOI: 10.1200/JCO.2004.22.90140.3617 |
0.35 |
|
| 2004 |
Mass RD, Fyfe G, Hambleton J, Kabbinavar F, Hurwitz H, Novotny W, Sarkar S. Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis Journal of Clinical Oncology. 22: 3616-3616. DOI: 10.1200/JCO.2004.22.90140.3616 |
0.344 |
|
| 2004 |
Hambleton J, Novotny WF, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation Journal of Clinical Oncology. 22: 3528-3528. DOI: 10.1200/JCO.2004.22.90140.3528 |
0.328 |
|
| 2004 |
Hedrick EE, Hurwitz H, Sarkar S, Griffing S, Novotny W, Grothey A. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC) Journal of Clinical Oncology. 22: 3517-3517. DOI: 10.1200/JCO.2004.22.90140.3517 |
0.364 |
|
| 2004 |
Spector N, Xia W, Burris HA, Hurwitz H, Dees C, Dowlati A, McKay C, Koch K, Harris J, Bacus S. Modulation of tumor growth and survival pathways in cancer patients treated with GW572016 Journal of Clinical Oncology. 22: 3003-3003. DOI: 10.1200/Jco.2004.22.90140.3003 |
0.322 |
|
| 2004 |
Fernando N, Morse M, Blobe G, Sutton L, Odogwu L, Honeycutt W, Bauer M, Mahon M, Daohai Y, Hurwitz H. 133 A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer European Journal of Cancer Supplements. 2: 43. DOI: 10.1016/S1359-6349(04)80142-3 |
0.327 |
|
| 2003 |
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 60-5. PMID 12506171 DOI: 10.1200/JCO.2003.10.066 |
0.414 |
|
| 2002 |
Onaitis MW, Noone RB, Fields R, Hurwitz H, Morse M, Jowell P, McGrath K, Lee C, Anscher MS, Clary B, Mantyh C, Pappas TN, Ludwig K, Seigler HF, Tyler DS. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Annals of Surgical Oncology. 8: 801-6. PMID 11776494 DOI: 10.1007/s10434-001-0801-2 |
0.308 |
|
| Show low-probability matches. |